Relmada Therapeutics Revises and Relaunches Pivotal Phase 3 Program for REL-1017
Ticker: RLMD · Form: DEF 14A · Filed: Apr 9, 2024 · CIK: 1553643
| Field | Detail |
|---|---|
| Company | Relmada Therapeutics, Inc. (RLMD) |
| Form Type | DEF 14A |
| Filed Date | Apr 9, 2024 |
| Risk Level | |
| Pages | 14 |
| Reading Time | 17 min |
| Sentiment | bullish |
Sentiment: bullish
Topics: Biotechnology, Pharmaceuticals, Clinical Trials, Depression Treatment, NMDA Receptor Antagonist
TL;DR
<b>Relmada Therapeutics is refocusing its development of REL-1017 for Major Depressive Disorder, revising its Phase 3 trials and initiating new studies.</b>
AI Summary
RELMADA THERAPEUTICS, INC. (RLMD) filed a Proxy Statement (DEF 14A) with the SEC on April 9, 2024. Relmada Therapeutics revised and relaunched its pivotal Phase 3 program for REL-1017, a treatment for Major Depressive Disorder (MDD). The company is focusing development on REL-1017 for adjunctive use in MDD treatment. Critical changes were implemented in the ongoing Phase 3 Study 302, evaluating REL-1017 25mg. A new trial, Study 304, for adjunctive MDD treatment has also been initiated. REL-1017 acts by blocking the NMDA receptor, distinct from conventional monoaminergic antidepressants.
Why It Matters
For investors and stakeholders tracking RELMADA THERAPEUTICS, INC., this filing contains several important signals. The company's strategic shift to focus on adjunctive MDD treatment for REL-1017 suggests a belief in its potential to address a significant unmet need in the market. The relaunch of the pivotal Phase 3 program with revised protocols indicates a commitment to optimizing the trial design for success, potentially leading to a more robust data package for regulatory submission.
Risk Assessment
Risk Level: — RELMADA THERAPEUTICS, INC. shows moderate risk based on this filing. The company's reliance on specific patient recruitment for its Phase 3 trials introduces a medium-level risk, as challenges in identifying and enrolling patients with true MDD pathophysiology could delay or impact study outcomes.
Analyst Insight
Investors should monitor the recruitment progress and interim data from the revised Study 302 and the new Study 304 for REL-1017 to assess the program's trajectory.
Key Numbers
- 25mg — REL-1017 Dosage (Dosage evaluated in Study 302)
Key Players & Entities
- RELMADA THERAPEUTICS, INC. (company) — Registrant
- REL-1017 (drug) — Treatment for Major Depressive Disorder
- Major Depressive Disorder (MDD) (condition) — Indication for REL-1017
- Study 302 (trial) — Phase 3 pivotal study
- Study 304 (trial) — New trial for adjunctive MDD
FAQ
When did RELMADA THERAPEUTICS, INC. file this DEF 14A?
RELMADA THERAPEUTICS, INC. filed this Proxy Statement (DEF 14A) with the SEC on April 9, 2024.
What is a DEF 14A filing?
A DEF 14A is a definitive proxy statement sent to shareholders before annual meetings, covering executive compensation, board nominations, and shareholder votes. This particular DEF 14A was filed by RELMADA THERAPEUTICS, INC. (RLMD).
Where can I read the original DEF 14A filing from RELMADA THERAPEUTICS, INC.?
You can access the original filing directly on the SEC's EDGAR system. The filing is publicly available and includes all exhibits and attachments submitted by RELMADA THERAPEUTICS, INC..
What are the key takeaways from RELMADA THERAPEUTICS, INC.'s DEF 14A?
RELMADA THERAPEUTICS, INC. filed this DEF 14A on April 9, 2024. Key takeaways: Relmada Therapeutics revised and relaunched its pivotal Phase 3 program for REL-1017, a treatment for Major Depressive Disorder (MDD).. The company is focusing development on REL-1017 for adjunctive use in MDD treatment.. Critical changes were implemented in the ongoing Phase 3 Study 302, evaluating REL-1017 25mg..
Is RELMADA THERAPEUTICS, INC. a risky investment based on this filing?
Based on this DEF 14A, RELMADA THERAPEUTICS, INC. presents a moderate-risk profile. The company's reliance on specific patient recruitment for its Phase 3 trials introduces a medium-level risk, as challenges in identifying and enrolling patients with true MDD pathophysiology could delay or impact study outcomes.
What should investors do after reading RELMADA THERAPEUTICS, INC.'s DEF 14A?
Investors should monitor the recruitment progress and interim data from the revised Study 302 and the new Study 304 for REL-1017 to assess the program's trajectory. The overall sentiment from this filing is bullish.
How does RELMADA THERAPEUTICS, INC. compare to its industry peers?
Relmada Therapeutics operates in the biopharmaceutical sector, focusing on the development of novel therapeutics for central nervous system disorders, specifically depression.
Are there regulatory concerns for RELMADA THERAPEUTICS, INC.?
The filing is a Definitive Proxy Statement (DEF 14A) filed under the Securities Exchange Act of 1934, providing information to shareholders regarding company matters, typically including executive compensation and director elections.
Risk Factors
- Patient Recruitment Challenges [medium — operational]: Success of clinical trials, particularly in depression, is highly dependent on recruiting appropriate patients with true MDD and controlling for placebo response.
Industry Context
Relmada Therapeutics operates in the biopharmaceutical sector, focusing on the development of novel therapeutics for central nervous system disorders, specifically depression.
Regulatory Implications
The filing is a Definitive Proxy Statement (DEF 14A) filed under the Securities Exchange Act of 1934, providing information to shareholders regarding company matters, typically including executive compensation and director elections.
What Investors Should Do
- Monitor patient recruitment rates and trial site performance for Study 302 and Study 304.
- Analyze any emerging efficacy or safety data from the ongoing Phase 3 trials.
- Review the company's upcoming proxy statements for updates on executive compensation and board composition.
Key Dates
- 2024-04-09: Filing Date — Definitive Proxy Statement filed
Glossary
- MDD
- Major Depressive Disorder (The primary indication for the drug REL-1017 being developed by Relmada Therapeutics.)
- NMDA receptor
- N-methyl-D-aspartate receptor (The target of REL-1017, suggesting a novel mechanism of action for treating depression.)
Year-Over-Year Comparison
This is a DEF 14A filing, which is a proxy statement. Previous filings may include 10-K, 10-Q, or other registration statements, but this specific filing focuses on shareholder voting matters and related disclosures.
Filing Stats: 4,333 words · 17 min read · ~14 pages · Grade level 13.5 · Accepted 2024-04-09 16:10:26
Filing Documents
- ea0200088-01.htm (DEF 14A) — 1746KB
- tflowchart_001.jpg (GRAPHIC) — 193KB
- tproxy_001.jpg (GRAPHIC) — 1115KB
- tproxy_002.jpg (GRAPHIC) — 804KB
- trelmada_logo.jpg (GRAPHIC) — 57KB
- 0001213900-24-031600.txt ( ) — 4734KB
Executive Compensation
Executive Compensation   16 Compensation Discussion & Analysis   16 Compensation Committee Report   22 Summary Compensation Table   22 Employment Agreements   22 Equity Compensation Plan Information   25 Outstanding Equity Awards at December 31, 2023   26 Pension Benefits   26 Potential Payments Under Severance / Change in Control Arrangements   27 Pay versus Performance Information   29 Principal Stockholders   30 Certain Relationships and Related Transactions   32 Principal Accounting Fees and Services   33 Proposal 1 — Election of Directors   34 Proposal 2 — Ratification of the Appointment of Marcum LLP   35 Proposal 3 — To approve an amendment to the Relmada Therapeutics, Inc. 2021 Equity Incentive Plan   36 Proposal 4 — To provide an advisory vote to approve executive compensation   46 Other Matters   47 Annual Report on Form 10-K   47 Householding of Proxy Materials   47 Proposals of Stockholders   48 Additional Information   49 Where You Can Find More Information   49 Stockholders Should Read the Entire Proxy Statement Carefully Prior to Returning Their Proxies i Table of Contents PROXY STATEMENT FOR ANNUAL MEETING OF STOCKHOLDERS GENERAL The enclosed proxy is solicited on behalf of the Board of Directors (the “Board”) of Relmada Therapeutics, Inc. for use at our 2024 annual meeting of stockholders to be held in a virtual -only (online) meeting format via live webcast on the Internet on May 24, 2024 at 9:30 a.m. Eastern Time. Voting materials, including this proxy statement and proxy card, are expected to be first delivered to all